The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Psychological well‐being in patients on ‘adequate’ doses of l‐thyroxine: results of a large, controlled community‐based questionnaire study
Abstract
Summary: objective Over 1% of the UK population is receiving thyroid hormone replacement with l‐thyroxine (T4). However, many patients complain of persistent lethargy and related symptoms on T4 even with normal TSH levels. To date there has been no large study to determine whether this is related to thyroxine replacement or coincidental psychological morbidity. We have therefore attempted to address this issue using a large, community‐based study. design and patients Computerized prescribing records of five general practices were used to identify 961 patients who had been on thyroxine for a minimum of 4 months from a population of 63 000 (1·5%), along with age‐ and sex‐matched controls. All 1922 individuals were sent a two‐page questionnaire, made up of the short form of the General Health Questionnaire (GHQ‐12), designed to detect minor psychiatric disorders in the community, and a 12‐question ‘thyroid symptom questionnaire’ (TSQ) in the same format. A covering letter explained that we were interested in ‘how patients felt on medication’ and made no direct reference to thyroxine. measurements Scores from the GHQ and TSQ were marked for each individual using the GHQ and Likert scoring methods. Patients’ latest TSH measurements were obtained from laboratory records. Comparisons were then made on scores for the total GHQ‐12, TSQ and individual questions between patients (P) and control (C) groups. Separate analyses were made comparing the patients with a normal TSH (nP) and the control group. results Five hundred and ninety‐seven (62%) of the patients (P) and 551 (57%) of the controls (C) responded and fully completed at least one of the two questionnaire. Three hundred and ninety‐seven responding patients (nP) had a TSH estimation performed in the previous 12 months with the last result being in the local laboratory normal range for TSH (0·1–5·5 or 0·2–6·0 mU/l, according to the assay method used). The responding P, nP and C populations were well matched for age (59·96, 59·73, 59·35 years) and sex (85%, 83%, 87% female). The number of individuals scoring 3 or more on the GHQ‐12 (indicating ‘caseness’) was 21% higher in P than C [185/572 (32·3%) vs. 137/535 (25·6%), P = 0·014] and 26% higher in nP than C [131/381 (34·4%) vs. 137/535 (25·6%), P < 0·005]. Stronger differences were seen with the TSQ scores [C = 187/535 (35·0%), P = 273/583 (46·8%), P < 0·001, P vs. C; and nP = 189/381 (48·6%), P < 0·001, nP vs. C]. Differences existed in chronic drug use and chronic disease prevalence between the control and patient groups, but the differences in GHQ and TSQ scores between the groups remained significant even after correction for these factors as well as age and sex in multiple regression analysis. conclusions This community‐based study is the first evidence to indicate that patients on thyroxine replacement even with a normal TSH display significant impairment in psychological well‐being compared to controls of similar age and sex. In view of the large numbers of people on thyroxine replacement, we believe that these differences, although not large, could contribute to significant psychological morbidity in a substantial number of individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients on levothyroxine display ongoing substantial impairment of psychological wellbeing compared with controls of similar age and sex.165”
From Hypothyroidism (2024) · cites this paper as [165]
In the citing paper
“Persistent symptoms in patients treated for hypothyroidism are common.”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [4]
In the citing paper
“a proportion of individuals have significant dissatisfaction with it, including ongoing significant impairment in psychological well -being compared to controls of similar age and sex. 4 -8”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [4]
In the citing paper
“There is now a consensus that a fraction of the LT4-treated hypothyroid patients with normal serum TSH levels remains symptomatic ( 6 , 7 , 23 , 24 ).”
From Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism (2021) · cites this paper as [6]
In the citing paper
“For some patients, however, the success story was limited by the persistence of residual cognitive symptoms and decrements in the quality of life (5–7).”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [5]
In the citing paper
“However, a minority of the patients remain symptomatic despite the normalization of serum thyrotropin levels.”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [5]
In the citing paper
“Limiting the analysis to patients with serum TSH in a narrow normal range (0.4-4.0 mU/l) gave similar outcomes: caseness was 35.1% in GHQ-12 and 48.5% in TSQ.”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [11]
In the citing paper
“After correction for age, sex, chronic diseases and chronic medication, the proportion of caseness was higher in patients than in controls, both in the GHQ-12 (34.4 vs. 25.6%,p = 0.012, odds ratio (OR) 1.48 [1.09-2.00])and in the TSQ (48.6 vs. 35.0%,p ! 0.001, OR 1.71 [1.29-2.25]).”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [11]
In the citing paper
“After correction for age, sex, chronic diseases and chronic medication, the proportion of caseness was higher in patients than in controls, both in the GHQ-12 (34.4 vs. 25.6%,p = 0.012, odds ratio (OR) 1.48 [1.09-2.00])and in the TSQ (48.6 vs. 35.0%,p ! 0.001, OR 1.71 [1.29-2.25]).”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [11]
In the citing paper
“The study provided evidence that patients on L-T4 replacement even with a normal serum TSH display significant impairment of psychological well-being compared to controls of similar age and sex.”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [11]
In the citing paper
“However, a proportion of individuals continue to suffer with symptoms despite achieving adequate biochemical correction.”
From Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee (2016) · cites this paper as [22]
In the citing paper
“Approximately 10%–15% of subjects with hypothyroidism on L-thyroxine (LT4) alone have persistent symptoms affecting their quality of life (QoL).”
In the citing paper
“Hypothyroid subjects on long-term LT4 alone have (a) a 15% excess of psychological caseness (5)”
In the citing paper
“We observed that in individuals on LT4 alone (n = 573), homozygosity for the Thr92Ala polymorphism was associated with reduced QoL (5).”
Citations
Cites
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
The detection of psychiatric illness by questionnaire
Levy, R. (1973) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(73)90039-1 · Cited by 2,707
THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY
Tunbridge, W. M. G., Evered, D. C., Hall, R., Appleton, D. R., BREWIS, M., CLARK, F., Evans, J. G., Young, E. T., Bird, T., & Smith, P. (1977) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1977.tb01340.x · Cited by 2,665
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.979 · Cited by 1,485
The use of the General Health Questionnaire as an indicator of mental health in occupational studies
Banks, M. H., Clegg, C., Jackson, P. R., Kemp, N. J., Stafford, E. M., & Wall, T. D. (1980) · Journal of Occupational Psychology · doi:10.1111/j.2044-8325.1980.tb00024.x · Cited by 690
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686
Larsen, P. R., Silva, J. E., & Kaplan, M. M. (1981) · Endocrine Reviews · doi:10.1210/edrv-2-1-87 · Cited by 546
Identification of a tHyroid Hormone Receptor That Is Pituitary-Specific
Hodin, R. A., Lazar, M. A., Wintman, B. I., Darling, D. S., Koenig, R. J., Larsen, P. R., Moore, D. D., & Chin, W. W. (1989) · Science · doi:10.1126/science.2539642 · Cited by 486
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 3×
“Relative hypothyroidism on T4 therapy titrated to a normal TSH would also be consistent with the observation that additional T4 (Carr et al., 1988) or partial T3 supplementation (Bunevicius et al., 1999) results in increases in well-being.”
BackgroundMari, J. D. J., & Williams, P. R. (1985) · Psychological Medicine · doi:10.1017/s0033291700031500 · Cited by 469
Research works printed but not linked: 2
- Roberts N.D., 1996, Psychological problems in thyroid disease, British Thyroid Foundation Newsletter, 18, 3
- 10.1210/jc.82.3.771 · DOI
Cited by
Sorted by citations
Items 201–300 of 513
Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge
Gild, M. L., Stuart, M. C., Clifton-Bligh, R. J., Kinahan, A., & Handelsman, D. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac223 · Cited by 28
The Challenges and Complexities of Thyroid Hormone Replacement
Kansagra, S. M., McCudden, C. R., & Willis, M. S. (2010) · Laboratory Medicine · doi:10.1309/lmb39th2fzgndgim · Cited by 25
Mazzaferri, E. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70110-0 · Cited by 25
The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
McAninch, E. A., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00446 · Cited by 27
“However, LT4-treated patients display significant impairment in psychological well-being compared to controls of similar age and sex (14).”
BackgroundInfluentialLombardi, C. P., Bocale, R., Barini, A., Barini, A., D’Amore, A., Boscherini, M., & Bellantone, R. (2017) · Endocrine · doi:10.1007/s12020-016-1003-9 · Cited by 23
Yavuz, D. G., Yazıcı, D., Keskin, L., Atmaca, A., Sancak, S., Saraç, F., Şahin, İ., Dikbaş, O., Hekimsoy, Z., Yalın, S., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00215 · Cited by 23
“A study evaluating elderly hypothyroid patients showed that more than 40% had low and 16% had high TSH levels, which were possibly correlated with lower weight (10).”
BackgroundHealth‐related quality of life in hypothyroidism—A population‐based study, the WHO MONICA Project
Ellegård, L., Krantz, E., Trimpou, P., & Landin‐Wilhelmsen, K. (2021) · Clinical Endocrinology · doi:10.1111/cen.14448 · Cited by 23
“Analgesics, n (%) 5 (7) 22 (6) Ns Number of medicationsa 2.”
BackgroundThyroid lobectomy for indeterminate FNA: not without consequences
Balentine, C. J., Domingo, R. P., Patel, R. R., Laucirica, R., & Suliburk, J. W. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.076 · Cited by 23
Springer, D. (2012) · InTech eBooks · doi:10.5772/1215 · Cited by 23
“However, some patients do not feel entirely well despite doses of T4 that are usually adequate (Saravanan et al., 2002).”
BackgroundPerros, P., Hegedűs, L. D., Nagy, E. V., Papini, E., Hay, H. A., Abad-Madroñero, J., Tallett, A. J., Bilas, M., Lakwijk, P., & Poots, A. J. (2022) · Thyroid · doi:10.1089/thy.2022.0324 · Cited by 24
“8,9,11 15–17 Persistent symptoms in patients on LT4 treatment result in multiple medical consultations, overinvestigation, 3 and alternative treatments.”
Pradhan, K. R., Chen, Y., Mostoufi‐Moab, S., Krull, K. R., Oeffinger, K. C., Sklar, C. A., Armstrong, G. T., Ness, K. K., Robison, L. L., Yasui, Y., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00627 · Cited by 22
“Mean ± SD 32 (24-40) 33 (25-40) 31 (23-38) <0.”
BackgroundQuality of life among patients on levothyroxine: A cross-sectional study
Qur‵an, T. A., Bataineh, Z. A., Al-Mistarehi, A.-H. W., Okour, A. M., Yonis, O. B., Khassawneh, A., AbuAwwad, R., & Qura’an, A. A. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.10.030 · Cited by 24
Posabella, A., Alber, A. B., Undeutsch, H. J., Droeser, R. A., Hollenberg, A. N., Ikonomou, L., & Kotton, D. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.666565 · Cited by 21
T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
Wiersinga, W. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.501 · Cited by 21
“pISSN 2093-596X · eISSN 2093-5978 [5,6].”
BackgroundToft, A. D., & Beckett, G. J. (2003) · BMJ · doi:10.1136/bmj.326.7384.295 · Cited by 32
Brigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 22
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease
Azizi, F., Mehran, L., Abdi, H., & Amouzegar, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae456 · Cited by 24
Tandon, A., Singh, R., Gupta, S., & Saroja, K. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_165_17 · Cited by 21
“A previous study showed that symptoms of hypothyroidism and ill health persist despite optimal LT4 treatment in >13% population.[7] In our study, we found that these symptoms were not more than controls.”
BackgroundCombination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V. S., Muller, I., Scholz, A., Dayan, C. M., & Okosieme, O. E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 22
Self-citationMuraca, E., Ciardullo, S., Oltolini, A., Zerbini, F., Bianconi, E., Perra, S., Villa, M., Cannistraci, R., Castoldi, G., Pizzi, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa097 · Cited by 21
Faustino, L. C., Kahaly, G. J., Frommer, L., Concepcion, E., Stefan–Lifshitz, M., & Tomer, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.691781 · Cited by 21
Dumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M., Giurcanu, M., & Bianco, A. C. (2022) · Thyroid · doi:10.1089/thy.2021.0304 · Cited by 20
Romero-Gómez, B., Guerrero-Alonso, P., Carmona‐Torres, J. M., Pozuelo‐Carrascosa, D. P., Laredo‐Aguilera, J. A., & Cobo‐Cuenca, A. I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123864 · Cited by 23
“These complaints refer to unsatisfactory weight gain after starting the treatment as well as to its impact on psychological well-being and body image, especially in women [39].”
BackgroundWound Complications in Thyroxine-Supplemented Patients Following Foot and Ankle Surgery
Grunfeld, R., Kunselman, A. R., Bustillo, J., & Juliano, P. J. (2011) · Foot & Ankle International · doi:10.3113/fai.2011.0038 · Cited by 20
Park, S. H., & Hong, S. H. (2018) · Journal of Medical Internet Research · doi:10.2196/11085 · Cited by 20
“Patients with hypothyroidism are treated with the most frequently prescribed drug in the United States, levothyroxine [1], but report poor quality of life despite the treatment [2-4].”
BackgroundHormone replacement therapy in hypopituitarism
Smith, J. C. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.5.1023 · Cited by 20
Perros, P. (2012) · European Thyroid Journal · doi:10.1159/000338637 · Cited by 20
Wartofsky, L. (2004) · Thyroid · doi:10.1089/105072504323030898 · Cited by 20
Liothyronine cost and prescriptions in England
Taylor, P. N., Razvi, S., Muller, I., Wass, J., Dayan, C. M., Chatterjee, K., & Boelaert, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30334-6 · Cited by 19
Self-citationLee, K. W., Shin, Y., Lee, S., & Lee, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.803024 · Cited by 20
Burlacu, M., Attanasio, R., Hegedűs, L. D., Nagy, E. V., Papini, E., Perros, P., Sawadogo, K. A., Bex, M., Corvilain, B., Daumerie, C., et al. (2022) · Thyroid Research · doi:10.1186/s13044-022-00121-9 · Cited by 20
Müssig, K., Besemer, B., Saur, R., Klingberg, S., Häring, H., Gallwitz, B., & Leyhe, T. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710001645 · Cited by 19
“For instance, patients receiving l-thyroxin replacement therapy for primary hypothyroidism showed disturbances in psychosocial well-being and cognitive performance despite euthyroidism (Leyhe et al., 2008; Saravanan et al., 2002; Wekking et al., 2005).”
BackgroundResultMemeh, K., Ruhle, B. C., Vaghaiwalla, T. M., Kaplan, E. L., Keutgen, X. M., & Angelos, P. (2020) · Surgery · doi:10.1016/j.surg.2020.03.028 · Cited by 18
Casula, S., Ettleson, M. D., & Bianco, A. C. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.003 · Cited by 19
Ahmad, A., Serry, Z. M. H., Elghaffar, H. A. A., Ghazi, H. A., & Elgayar, S. L. (2023) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2023.101795 · Cited by 18
Clinical Diagnostic Gene Expression Thyroid Testing
Steward, D. L., & Kloos, R. T. (2014) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2014.04.009 · Cited by 18
Optimal Hormone Replacement Therapy in Hypothyroidism - A Model Predictive Control Approach
Wolff, T. M., Dietrich, J. W., & Müller, M. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884018 · Cited by 18
Combination Therapy for Hypothyroidism: Rationale, Therapeutic Goals, and Design
Madan, R., & Celi, F. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00371 · Cited by 18
Azizi, F., Abdi, H., Cheraghi, L., & Amouzegar, A. (2020) · Thyroid · doi:10.1089/thy.2020.0433 · Cited by 17
“Inaddition, impairmentinpsychologicalwell-being(40),decreasedresting energyexpenditure(41),lowerserumT3:thyroxine(T4)ratio, andincreasedtotalandlow-densitylipoprotein-cholesterol(42) havebeenreportedinlevothyroxine-treatedpatientswhen comparedwithnormalcontrols.”
A survey of the young person’s experience of Graves’ disease and its management
Lane, L. C., Rankin, J. M., & Cheetham, T. D. (2020) · Clinical Endocrinology · doi:10.1111/cen.14359 · Cited by 17
“Female 21 (81) Male 5 (19) Age in years (range) 18 (8-28) Current education/occupation School 13 (50) Higher education 2 (8) Employed 9 (34) Unemployed 2 (8) Clinical characteristic Other medical diagnoses 8 (31)”
BackgroundDew, R., Okosieme, O. E., Dayan, C. M., Eligar, V. S., Khan, I. N., Razvi, S., Pearce, S. H. S., & Wilkes, S. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0457-z · Cited by 17
“Furthermore, hypothyroid patients even with apparently normal TSH levels report having reduced psychological well-being [18] and poor quality of life [19].”
Self-citationTrends in costs and prescribing for liothyronine and levothyroxine in England and wales 2011–2020
Stedman, M., Taylor, P., Premawardhana, L., Okosieme, O., Dayan, C., & Heald, A. H. (2021) · Clinical Endocrinology · doi:10.1111/cen.14414 · Cited by 16
“It has been stated that 5%– 10% of people with hypothyroidism may be unresponsive to levothyroxine.(2) However, only a small proportion of these are currently receiving liothyronine.”
BackgroundInfluentialSelf-citationOto, Y., Muroya, K., Hanakawa, J., Asakura, Y., & Adachi, M. (2015) · Thyroid Research · doi:10.1186/s13044-015-0023-5 · Cited by 16
“It has been reported that 5–10 % of hypothyroid patients treated with L-T4 therapy suffered from symptoms indicative of persistent hypothyroidism such as impaired well-being, diminished cognitive functions, anxiety, and depression despite adequate TSH suppression [17–19].”
BackgroundIdrees, T., Prieto, W. H., Casula, S., Ajith, A., Ettleson, M., Narchi, F. A. A., Russo, P. S. T., Fernandes, F., Johnson, J., Mayampurath, A., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab038 · Cited by 17
“However, there is evidence that a fraction of LT4-treated patients remains symptomatic despite normal serum TSH levels [6-9].”
BackgroundGene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism
Penna, G., Salas-Lucia, F., Ribeiro, M. O., & Bianco, A. C. (2023) · Endocrine · doi:10.1007/s12020-023-03528-y · Cited by 17
“Nonetheless, the fi ndings (i) that LT4 exhibits variable effectiveness in restoring clinical and biochemical euthyr-oidism [2 – 4], (ii) that Thr92Ala-DIO2 is associated with increased Body Mass Index (BMI) and relative insulin resistance in obese Caucasians [5], and with reduced quality of life…”
Precision Medicine Comes to Thyroidology
Ladenson, P. W. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3695 · Cited by 16
Hypothyroidism and Thyroiditis
Brent, G. A., & Weetman, A. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00013-7 · Cited by 16
Systemic Thyroid Hormone Status in Treated Graves’ Disease
Azizi, F., Amouzegar, A., Tohidi, M., Hedayati, M., Cheraghi, L., & Mehrabi, Y. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.95385 · Cited by 16
“Recent studies have shown that patients on LT4 replacement exhibit significant impairment in psychological well-being (5) and decreased resting energy expenditure when compared to normal controls (4).”
BackgroundThyroid Gland Organoids: Current Models and Insights for Application in Tissue Engineering
Ogundipe, V. M. L., Plukker, J. T. M., Links, T. P., & Coppes, R. P. (2022) · Tissue Engineering Part A · doi:10.1089/ten.tea.2021.0221 · Cited by 16
Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review
Razvi, S., Mrabeti, S., & Luster, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0205 · Cited by 15
Mehuys, E., Lapauw, B., T'Sjoen, G. G., Christiaens, T. C., Sutter, A. D., Steurbaut, S., Tongelen, I. V., & Boussery, K. (2023) · Thyroid · doi:10.1089/thy.2023.0066 · Cited by 17
Dew, R., King, K., Okosieme, O. E., Pearce, S. H. S., Donovan, G., Taylor, P. N., Leese, G., Hickey, J., Razvi, S., Dayan, C. M., et al. (2017) · BJGP Open · doi:10.3399/bjgpopen17x100977 · Cited by 17
Self-citationSharma, S., Tobin, V., Vas, P. R. J., & Rayman, G. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00671 · Cited by 15
Razvi, S., & Gottwald‐Hostalek, U. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1570769 · Cited by 16
Does Combination T4 And T3 Therapy Make Sense?
McDermott, M. T. (2012) · Endocrine Practice · doi:10.4158/ep12076.ra · Cited by 15
Brown Adipose Tissue Response to Cold Stimulation Is Reduced in Girls With Autoimmune Hypothyroidism
Law, J., Morris, D. E., Astle, V., Finn, E., Muros, J. J., Robinson, L., Randell, T. L., Denvir, L. A., Symonds, M. E., & Budge, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00342 · Cited by 15
“Additionally, levothyroxine monotherapy does not always fully resolve symptoms of hypothyroidism, and quality of life scores remain below those of healthy controls [71, 72], possibly due to a lack of euthyroid status at the tissue level [73–75].”
BackgroundLong-term antithyroid drug therapy
Cooper, D. S. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000656 · Cited by 16
“The reasons for this dramatic change are multiple, and include patient dissatisfaction with the therapy of permanent hypothyroidism [13,14], radiation exposure, the controversy over the potential for subsequent malignancy [15 & ], and the prospect of worsening or the new onset of thyroid eye disease after radioiodine…”
BackgroundHeald, A. H., Premawardhana, L., Taylor, P., Okosieme, O., Bangi, T., Devine, H., Livingston, M., Javed, A., Moreno, G. Y. C., Watt, T., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14967 · Cited by 14
“The severity and chronicity of experienced symptoms and the fact that the majority of patients found these symptoms to be significantly alleviated, can be viewed as supportive evidence for the potential benefit of NDT when this is prescribed after careful consideration of other differential…”
BackgroundSelf-citationPrevalence of Dio2(T92A) polymorphism and its association with thyroid autoimmunity.
Guerra, A., Sapio, M. R., Carrano, M., Stasi, V. D., Volpe, A., Murino, A., Izzo, G., & Vitale, M. (2013) · PubMed · doi:10.3275/8618 · Cited by 14
Progress Toward and Challenges Remaining for Thyroid Tissue Regeneration
Romitti, M., & Costagliola, S. (2023) · Endocrinology · doi:10.1210/endocr/bqad136 · Cited by 13
Diagnosis and treatment of hypothyroidism in old people
Borzì, A. M., Biondi, A., Basile, F., & Vacante, M. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01579-8 · Cited by 14
Cho, Y. Y., Kim, H. J., Jang, H. W., Kim, T. H., Ki, C., Kim, S. W., & Chung, J. H. (2017) · Endocrine · doi:10.1007/s12020-017-1307-4 · Cited by 16
Hoermann, R., Midgley, J. E. M., Dietrich, J. W., & Larisch, R. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817716401 · Cited by 13
Klonizakis, P., Klaassen, R. J., Sousos, N., Liakos, A., Τσάπας, Α., & Vlachaki, E. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3122-7 · Cited by 13
Viard, D., Parassol, N., Romani, S., Obberghen, E. V., Rocher, F., Berriri, S., & Drici, M. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12446 · Cited by 13
Mele, C., Tagliaferri, A., Pagano, L., Soranna, D., Scacchi, M., Aimaretti, G., Biondi, B., & Marzullo, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00773 · Cited by 14
Hypothyroidism and Myxedema Coma
Wiersinga, W. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00085-x · Cited by 13
Thyroxine Monotherapy After Thyroidectomy
Cooper, D. S. (2008) · JAMA · doi:10.1001/jama.299.7.817 · Cited by 13
Real Practice Assessment of Persistent Symptoms After Initiation of Levothyroxine
Hidalgo, J., Vallejo, B. A., Soto Jacome, C., Ayala, I. N., Cordova, S., Duran, M., Golembiewski, E., Toro-Tobon, D., & Brito, J. P. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.10.132 · Cited by 12
Raij, T., & Raij, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1358404 · Cited by 15
Jonklaas, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934003 · Cited by 12
Brown, B. T., Bonello, R., Pollard, H. P., & Graham, P. L. (2010) · Trials · doi:10.1186/1745-6215-11-106 · Cited by 12
“Saravanan et al report that substantial numbers of hypothyroid sufferers continue to experience the plethora of hypothyroid symptoms despite demonstrating hormone levels within reference ranges [10].”
BackgroundBoronat, M., González-Lleó, A. M., Rodríguez-Pérez, C., Feldt‐Rasmussen, U., López-Plasencia, Y., Rasmussen, Å. K., Alberiche-Ruano, M. P., Hegedűs, L. D., Alvarado-Martel, D., Bonnema, S. J., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.06.010 · Cited by 13
Arafa, M. A. A., Gouda, Z. A., El‐naseery, N. I., Abdelnour, H. M., Hanafy, S. M., Mohamed, A. F., & Abo-Ouf, A. M. (2018) · Cells Tissues Organs · doi:10.1159/000497297 · Cited by 12
“Furthermore, these medications are lifelong and require caution during use because of their interactions with other medications [Saravanan et al., 2002].”
BackgroundHirtz, R., Keesen, A., Hölling, H., Hauffa, B. P., Hinney, A., & Grasemann, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00454 · Cited by 11
“(12–16)], even in patients treated with levothyroxine (1, 17).”
BackgroundInfluentialMoncayo, R., & Moncayo, H. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.03.004 · Cited by 12
Ashoor, G., Rotas, M., Maíz, N., Kametas, N. A., & Nicolaides, K. H. (2010) · Fetal Diagnosis and Therapy · doi:10.1159/000314906 · Cited by 12
“The symptoms of hypothyroidism in patients treated with levothyroxine are abolished only with a dose resulting in supernormal FT 4 and subnormal TSH [ ,”
BackgroundHypothyroidism and Myxedema Coma
Wiersinga, W. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00088-3 · Cited by 12
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf449 · Cited by 11
“However, observational studies suggest that a proportion of patients on LT4 alone continue to display impairment of psychological well-being compared with controls of similar age and sex (8, 9).”
Self-citationVariable transduction of thyroid hormone signaling in structures of the mouse brain
Sinkó, R., Salas-Lucia, F., Mohácsik, P., Halmos, E., Wittmann, G., Egri, P., Bocco, B. M. L. C., Batistuzzo, A., Fonseca, T. L., Fekete, C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415970122 · Cited by 13
“This is concerning, given that some L - T4 - treated patients do exhibit cognitive impairment despite normalization of TSH ( 4 , 40 – 42 ).”
Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies
Rossi, L., Paternoster, M., Cammarata, M., Bakkar, S. Y., & Miccoli, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1582734 · Cited by 15
Wang, F., Wu, Z., Zha, X., Cai, Y., Wu, B., Jia, X., & Zhu, D.-F. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6977 · Cited by 12
“However, previous clinical studies have indicated that patients with hypothyroidism who were properly treated with T4 have not always fully recovered from the symptoms affecting the central nervous system, such as the cognitive functioning and well-being (16-18).”
Change in Thyroid Hormone Metabolite Concentrations Across Different Thyroid States
Jongejan, R. M. S., van Velsen, E. F. S., Meima, M. E., Klein, T., van den Berg, S. A. A., Massolt, E. T., Visser, W. E., Peeters, R. P., & de Rijke, Y. B. (2021) · Thyroid · doi:10.1089/thy.2021.0453 · Cited by 11
Ruíz-Pacheco, M. G., Hernández, I., Hernández-Estrella, G., Basurto, L., Vargas‐Ortega, G., González‐Virla, B., Molina-Ayala, M., Hernández-Martínez, A. F., Luengas-Mondragón, R., Hernández-Allende, A. A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030811 · Cited by 11
“According to the recommendations, patients with hypothyroidism should be treated with levothyroxine monotherapy [8,9]; however, the addition of liothyronine has been proposed as a beneficial and safe therapy in the management of hypothyroidism symptoms, mainly in quality of life [20,21,27], weight management, fatigue,…”
MethodSerum microRNA profiles in athyroid patients on and off levothyroxine therapy
Massolt, E. T., Chaker, L., Visser, T. J., Gillis, A., Dorssers, L. C. J., Beukhof, C. M., Kam, B. L. R., Franssen, G. J. H., Brigante, G., van Ginhoven, T. M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194259 · Cited by 11
LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?
Azizi, F., Amouzegar, A., Mehran, L., & Abdi, H. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.100870 · Cited by 12
Regeneration of Thyroid Glands in the Spleen Restores Homeostasis in Thyroidectomy Mice
Tian, X., Yin, Z., Li, Z., Wang, Z., Xing, Z., Liu, C., Wang, L., Wang, C., Zhang, J., & Dong, L. (2023) · Advanced Science · doi:10.1002/advs.202305913 · Cited by 9
Hoff, G. S., Bernklev, T., Johnsen, L., Reitsma, L. C., Sina, D., Lauzike, A., Gibbs, C., Lende, T. H., Narvestad, J. K., Kildahl, R., et al. (2024) · Journal of Thyroid Research · doi:10.1155/2024/5518720 · Cited by 10
“It has been hypothesized that persistent symptoms may be related to extra-thyroidal autoimmune reactions rather than hypothyroidism [6, 7] and that complete removal of antigenic thyroid tissue may attenuate the autoimmune response and relieve symptoms [8, 9].”
BackgroundZhang, H., Tong, W., Zeng, W., Luo, H., Zhang, L., Feng, J., Xiao, Y., & Wang, G. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627787 · Cited by 13
Azizi, F., Saadat, N., Takyar, M. A., Abdi, H., Mehran, L., & Amouzegar, A. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1476 · Cited by 10
Impact of death anxiety on mental health during COVID-19: The mediating role of the meaning in life
Jin, Y., Zeng, Q., Cong, X., An, J., & Zheng, P. (2023) · Journal of Pacific Rim Psychology · doi:10.1177/18344909231165187 · Cited by 11
“A total score higher than 15 indicates a mental health problem tendency (Saravanan et al., 2002).”
BackgroundRiis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
“12,56 In future studies, preferably in the setting of RCTs, the focus should be on patients with persistent symptoms, low circulating T3 levels, or those with speci fi c DIO2 gene variants.”
Gottwald‐Hostalek, U., & Razvi, S. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2071059 · Cited by 10
Patients on Appropriate T4Replacement Are as Content as They Would Be on Any Thyroid Hormone
Laurberg, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032136 · Cited by 10
The future endocrine patient. Reflections on the future of clinical endocrinology.
Lamberts, S. W., Romijn, J., & Wiersinga, W. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490169 · Cited by 14
Temporal Pole Responds to Subtle Changes in Local Thyroid Hormone Signaling
Marcelino, C. P., McAninch, E. A., Fernandes, G. W., Bocco, B. M. L. C., Ribeiro, M. O., & Bianco, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa136 · Cited by 10
Brown, B. T., Graham, P. L., Bonello, R., & Pollard, H. P. (2015) · Chiropractic & Manual Therapies · doi:10.1186/s12998-015-0068-5 · Cited by 10
“These baseline neuropsychiatric findings were expected given the continued symptomatology reported large community based samples of patients with treated hypothyroidism [14, 16, 23].”
BackgroundToft, A. D. (2005) · Thyroid · doi:10.1089/thy.2005.15.124 · Cited by 10
“The experience of most endocrinologists is that the majority of patients feel well only with a dose of thyroxine that results in a high normal serum T 4 and low normal serum TSH, and those patients with continuing symptoms despite “adequate doses of thyroxine” (13) may be slightly under-replaced.”
Functional Analysis of Novel Genetic Variation in the Thyroid Hormone Activating Type 2 Deiodinase
Zevenbergen, C., Klootwijk, W., Peeters, R. P., Medici, M., de Rijke, Y. B., Huisman, S. A., Goeman, H. J. M., Boot, E., de Kuijper, G. M., de Waal, K. H., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2281 · Cited by 9
“2014-2281 J Clin Endocrinol Metab, November 2014, 99(11):E2429–E2436 jcem.”
BackgroundMethodInfluentialPhan, G. Q., Yavuz, S., Stamatouli, A. M., Madan, R., Chen, S., Grover, A. C., Nilubol, N., Bedoya, P., Trankle, C. R., Markley, R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1522753 · Cited by 9
Metadata
- Authors
- Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M.
- Affiliations
- Weston General Hospital (GB)
- Bristol Royal Infirmary (GB)
- University of Bristol (GB)
- Corresponding author
- Dayan, C. M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2002-10-22
- Volume
- 57
- Issue
- 5
- Pages
- 577-585
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1888479777
- Cited by
- 514
- References
- 33
- Citations by year
- 2026: 12 · 2025: 27 · 2024: 26 · 2023: 30 · 2022: 45 · 2021: 33 · 2020: 37 · 2019: 33 · 2018: 27 · 2017: 26 · 2016: 31 · 2015: 21 · 2014: 25 · 2013: 15 · 2012: 16
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- levothyroxine, thyroid hormone replacement, psychological well-being, thyroid symptoms, thyroid-stimulating hormone, psychiatric morbidity, lethargy, General Health Questionnaire, community-based study, adverse drug reactions, quality of life
- MeSH terms
- Adolescent, Adult, Aged, Drug Administration Schedule, Female, Humans, Hypothyroidism, Male, Middle Aged, Psychiatric Status Rating Scales, Surveys and Questionnaires, Regression Analysis, Thyrotropin, Thyroxine, Chi-Square Distribution, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
